Turret Capital Management announced it has launched Sable, a New York-based “biotech beauty” company backed by pre-seed funding from Turret Capital and SOSV, positioning the new brand at the intersection of consumer body care, aesthetic maintenance, and science-led product development.
Sable’s initial product strategy centers on topical body creams derived from scientific work originating at Columbia University Medical Center. The company said preclinical studies tied to the underlying discovery showed a novel ingredient could be selectively taken up by fat cells and reduce fat cell volume by as much as 70%. Sable said it has exclusively licensed the asset and is developing it into an advanced topical formulation aimed at visible improvements in body contours and skin vitality.
The company is launching into a market it described as increasingly shaped by demand for body-sculpting procedures and wellness-driven lifestyle shifts, including the rising use of GLP-1 medications. Sable said its formulations are designed to support consumers seeking targeted contouring for specific areas, maintenance during significant wellness transitions, and ongoing aesthetic optimization following professional treatments.
Turret Capital, which focuses on commercializing healthcare technologies, framed Sable as part of its broader effort to scale ventures rooted in biotech and medical innovation. SOSV, a global venture investor across deep tech and life sciences, is backing the launch alongside Turret as Sable moves from research translation into consumer-facing product development.
KEY QUOTE:
“Sable represents the next frontier of science-to-shelf beauty. By translating complex research into thoughtfully designed consumer products, we’re redefining the limits of topical body care. Sable is focused on helping people achieve and maintain their desired aesthetic look through evidence-based innovation that supports long-term body confidence”.
Daniel Chai, MD, Founder and CEO, Sable
